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BACKGROUND: Recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell
carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving
42 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic
review examines current prognostic markers in SCC of the anus.
METHODS: An extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of
clinical outcome following treatment primarily with chemoradiotherapy.
RESULTS: In all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these
biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21
were the only markers shown to be of prognostic value in more than one study.
CONCLUSIONS: An array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer.
However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further
studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets
for new therapeutic strategies.
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Anal cancer is a disease whose incidence has risen markedly in
several parts of the world including Europe and the United States
(Rousseau et al, 2005). Of notable concern is the significant impact
of this disease on the young male population, with incidence rates
of up to 37 per 100000 in homosexual men (Place et al, 2001). Of
men who have sex with men (MSM), 95% are seropositive for the
implicated viral pathogen, human papilloma virus (subtypes 16,
18, 32 and 34) (Palefsky et al, 2005). Also, 81% of MSM have anal
intraepithelial neoplasia (AIN; premalignant lesion) (Palefsky et al,
2005). HPV is associated with the proteins E6 and E7 that can
silence important tumour-suppressor proteins in normal cells
(Mammas et al, 2008). These proteins, namely p53 and Rb,
normally exert apoptotic cellular effects to prevent disordered cell
growth (Mammas et al, 2008). Removal of this growth restriction
may lead to malignant transformation (Mammas et al, 2008). At
the time of diagnosis, up to 50% of patients have locoregional
disease with visceral metastases present in 10% of patients
(UKCCCR Anal Cancer Trial Working Party, 1996; Rousseau
et al, 2005). The most common sites are the liver and lungs
(Rousseau et al, 2005).
In the past, the mainstay of treatment for anal carcinoma was
abdominoperineal resection with formation of a permanent end
colostomy. Over the last two decades, combined chemoradio-
therapy pioneered in the 1970s by Nigro et al (1974) has become
the standard of care with salvage abdominoperineal resection
reserved for a small proportion of cases refractory to chemo-
radiotherapy (Place et al, 2001). Despite respectable treatment
response rates in non-metastatic disease with overall survival rates
of 60–75%, only 10% of patients with distant metastases survive 2
years from the time of their diagnosis (Cummings, 2006; Das et al,
2008). Furthermore, it is evident that treatment response shows a
degree of heterogeneity between individual patients within a
specific stage category, suggesting a spectrum of chemoradiation
sensitivity. Furthermore, the acute and long-term toxicity asso-
ciated with standard chemoradiation schedules are considerable,
and therefore predictors of response and novel therapeutic
approaches are required to allow treatments to be tailored
according to treatment sensitivity.
Clinical and pathological factors have been evaluated extensively
with regard to outcomes in anal cancer. Clinicopathological
parameters have not consistently enabled prediction of response
to currently available treatment modalities. This had led to
considerable interest in prognostic and predictive biomarkers as
putative means to improving patient survival. A prognostic
biomarker gives information regarding the patient’s overall
outcome, irrespective of the therapy received, whereas a predictive
biomarker provides information about the effect of a specific
therapeutic intervention (Oldenhuis et al, 2008). Molecular
analysis may permit the tailoring of treatments to individual
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spatients and help identify new therapeutic targets. Tyrosine
kinases (TKs), which have an established role in malignant trans-
formation of human cells, have served as major target in cancer
treatment strategies such as imatinib, the BCR-ABL TK inhibitor
used in the treatment of chronic myeloid leukaemia and GISTs
(Madhusudan and Ganesan, 2004). In recent years, the epidermal
growth factor receptor (EGFR – particularly HER-1 and HER-2)
has been the most extensively investigated TKs and now forms a
significant component of the ongoing research into molecular
targeted cancer therapy. In non-small cell lung cancer, mutations
in the TK domain of the EGFR have been shown to be associated
with a high treatment response rate to the EGFR TK inhibitor
erlotinib (Paz-Ares et al, 2006). Randomised trials in metastatic
colorectal cancer have demonstrated that use of monoclonal
antibodies directed against EGFR (HER-1), namely cetuximab and
panitumumab, is associated with favourable outcomes in patients
expressing the wild-type form of K-ras proto-oncogene (Siddiqui
and Piperdi, 2009). Therefore, a search for putative predictive
markers in anal cancer is warranted in order to explore whether
these and other targeted treatments should be assessed in the
setting of early and/or metastatic anal cancer.
The purpose of this systematic review was to evaluate the
literature available to-date on biological and molecular prognostic
factors in squamous cell carcinoma (SCC) of the anus.
MATERIALS AND METHODS
A systematic review was undertaken to identify the prognostic
significance of biomarkers in anal cancer. During this process,
reference to the AMSTAR measurement tool was made (Shea et al,
2007). This 11-component assessment tool was constructed to
assess the methodological quality of systematic reviews. Although
the reproducibility and construct validity of this tool is currently
uncertain, preliminary findings suggest that AMSTAR has good
construct validity and is a reliable tool for the methodological
assessment of systematic reviews.
A comprehensive literature search was performed by two
independent reviewers (TL and DK) using the PubMed, Web of
Science, Embase and Google Scholar databases. This search was
conducted up to 9 January 2010. The following keywords were
used in various combinations: ‘anal cancer’, ‘biomarkers’, ‘mole-
cular markers’, ‘biological markers’, ‘prognosis’ and ‘clinical
outcome’ in addition to searching for individual biomarkers.
Further relevant studies were identified by searching the references
cited in identified publications and also by utilisation of the
PubMed ‘related articles’ tool (Shalhoub et al, 2009).
No exclusions from the analysis were made based on the date of
the publication or the type of the study. Articles not published in
the English language were excluded. Studies were excluded because
of the absence of (1) any data regarding clinical outcome or
prognosis; (2) potentially extractable or a complete set of data
considered necessary; (3) peer review status; and (4) the use of
chemotherapy/radiotherapy as a primary treatment. Studies were
also excluded if they referred to AIN rather than carcinoma.
In addition to patient demographics and tumour characteristics,
outcomes of interest related to the study of potential biomarkers
included the type of treatment received, tumour recurrence and
patient relapse rates, disease-free survival (DFS), overall survival
and mortality.
RESULTS
Using the search methods described above, a total of 179 articles
were identified. Of these, 73 were initially excluded as they were
not studies of anal cancer. Eight articles were not related to the
study of biomarkers. A further 30 articles were also excluded by
abstract review; 13 of these were review articles and 17 were case
reports. Of the remaining 68 references searched in full, 11 studies
were excluded as they included the premalignant form, AIN, with
no discrimination of results between the two disease groups.
Another 17 studies were excluded as they combined data from
human cancers of different anatomical locations (including anal
carcinoma) with no breakdown of results for the various cancer
types. Sixteen studies of biomarkers in anal cancer were excluded
as correlation with prognosis was not assessed. Finally, three
studies failed to meet the inclusion criteria, as the primary form
of treatment in these studies was radical surgery rather than
chemoradiation. Ultimately, 21 studies remained for full inclusion
in this literature review (Figure 1) (Fontana et al, 1991; Tanum
et al, 1992; Goldman et al, 1993; Holm and Tanum, 1996; Tanum
and Holm, 1996; Allal et al, 1998, 2003, 2004; Grabenbauer et al,
1998; Bonin et al, 1999; Indinnimeo et al, 1999, 2000a,b, 2001;
Wong et al, 1999; Holm et al, 2001; Le et al, 2005; Alvarez et al,
2006; Nilsson et al, 2006; Bruland et al, 2008; Ajani et al, 2009).
The 21 studies included in the analysis evaluated a number of
different of biomarkers, which are discussed below and illustrated
in Figure 2.
Tumour-suppressor genes
The primary role of tumour-suppressor genes is to regulate cell
division, differentiation and apoptosis in order to prevent genetic
damage that may lead to the development of cancerous cells. p53,
p21, p27, p16 and the retinoblastoma (RB) gene are examples of
such genes whose prognostic significance has been studied in anal
carcinoma.
p53 The p53 gene located on chromosome 17p13.1 encodes a
protein that has an important role in cell cycle regulation and
apoptosis (Kastan et al, 1995). Additionally, wild-type p53 has
been linked with cellular DNA damage repair and inhibition
of angiogenesis (Vogelstein et al, 2000). This gene has been
extensively studied in several human cancers, and mutations of
this gene are considered to be the commonest genetic anomaly in
human tumours (Wong et al, 1999). Evidence suggests that
mutated p53 can lead to genomic instability and permit malignant
transformation of previously non-cancerous cells (Finlay et al,
1989).
179 articles identified by
initial search methods
68 articles searched in full
73 articles were not
studies of anal cancer
13 review articles
17 case reports
21 studies included in the
final analysis
47 articles excluded due to the following:
- 11 studies of AIN and anal cancer
- 17 studies of a variety of cancers
- 16 studies had no prognostic data
   reported
-3 studies in which treatment was
    primarily surgical 
Figure 1 Flow diagram representing the selection process for the studies
included in the final analysis.
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sEight studies evaluated the prognostic significance of p53 in
anal carcinoma (Table 1) (Tanum and Holm, 1996; Bonin
et al, 1999; Indinnimeo et al, 1999; Wong et al, 1999; Allal et al,
2003; Le et al, 2005; Nilsson et al, 2006; Ajani et al, 2009).
Immunohistochemistry was utilised in all studies to assess nuclear
p53 status in anal carcinoma paraffin-embedded specimens.
Wild-type p53 protein has a relatively short half-life and is
less readily detectable by immunohistochemical staining. How-
ever, mutated p53 typically undergoes a conformational change
that stabilises the protein, resulting in nuclear accumulation
and therefore positive staining (Neal et al, 2006). In these
studies, p53 was considered to be overexpressed if 45% of
tumour cells stained positive for nuclear p53. The proportion of
patients with anal carcinoma overexpressing p53 ranged from
34 to 100%.
Two studies demonstrated a significant correlation between p53
status and clinical outcome in anal carcinoma. Allal et al (2003)
found through multivariate analysis that patients with p53-positive
tumours had a lower rate of locoregional control (RR, 0.38;
P¼0.03) and shorter DFS (RR, 0.29; P¼0.003). Similarly, Wong
et al (1999) showed that p53 overexpression was an independent
adverse marker for DFS in patients with anal carcinoma treated
with combined chemoradiotherapy (P¼0.01). Another study
consisting of 64 patients reported a trend using univariate analysis
towards higher locoregional failure rates following chemo-
radiotherapy in patients with mutant p53 compared with those
with the wild-type form (48 vs 27%, P¼0.14) (Bonin et al, 1999).
However, this finding did not reach statistical significance and no
further correlation was seen with either DFS or overall survival
(Bonin et al, 1999). The five remaining studies examining p53 did
not identify any correlation between its overexpression and
clinicopathological parameters or survival (Tanum and Holm,
1996; Indinnimeo et al, 1999; Le et al, 2005; Nilsson et al, 2006;
Ajani et al, 2009).
p21 Activation of the p21 protein, a cyclin-dependent kinase
(CDK) inhibitor, results in cell cycle arrest at the G1- to S-phase
transition in mammals (Harper et al, 1993). Its effector functions
Biomarkers studied in anal cancer
Tumour
suppressor
EGFR Apoptotic
regulators
Cyclins Proliferation
and invasion
Angiogenesis Tumour
markers
Hedgehog
signalling
Telomerase
p53 EGFR/HER-1 NF-B Cyclin A Ki-67 VEGF
MVD
CD31
CEA
SCCAg SHH
Gli-1
hTERT
MiB1
PCNA
McM7
Nm23
Capthesin D
Cyclin D1
Cyclin E
Bax
Bcl-2
Mcl-1
M30
HER-2 p21
p27
p16
Rb
Figure 2 The classes and subclasses of biomarkers evaluated in the final 21 studies (highlighted in bold are the biomarkers that were associated with
outcome in at least one study).
Table 1 Studies of tumour-suppressor genes (p53) in anal carcinoma
Authors Year Biomarker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up
period in
months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients)
Correlation with
prognosis
Tanum and
Holm
1996 p53 97 IHC 97 chemo-
radiotherapy
0 60 34% Not reported No prognostic significance
identified
Bonin et al 1999 p53 64 IHC 64 chemo-
radiotherapy
0 (57) 48% 48 vs 33% DFS No prognostic significance
identified
Indinnimeo
et al
1999 p53 14 IHC Not reported Not reported 57.6 60% 44 vs 40% DFS No prognostic significance
identified
Wong et al 1999 p53 49 IHC 49 chemo-
radiotherapy
0 (54) 51% 62 vs 67%
5-year DFS
p53 expression associated
with reduced DFS (P¼0.01)
Allal et al 2003 p53 98 IHC 47 radiotherapy
alone 51 chemo-
radiotherapy
0 (124) 43% 75 vs 55%
5-year DFS
p53 expression associated
with reduced local tumour
control (P¼0.03) and
reduced DFS (0.003)
Le et al 2005 p53 21 IHC 21 chemo-
radiotherapy
0 Not reported 100% Not reported No prognostic significance
identified
Nilsson et al 2006 p53 214 IHC Not reported 7 local excision,
6A P R
Not reported 50% Not reported No prognostic significance
identified
Ajani et al 2009 p53 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼1.22
for DFS
No prognostic significance
identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; IHC¼immunohistochemistry; Rb¼retinoblastoma; RR¼relative risk.
aPatients included in final
biomarker analysis.
bIn studies where patients have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as
biomarker positive.
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sare predominantly induced by p53 and it is considered to be a
mediator of the tumour-suppressor activity of p53 (el-Deiry et al,
1993). However, it also appears to function via mechanisms
independent of the p53 gene in response to cellular DNA damage
(Roninson, 2002). Underexpression of p21 has been associated
with poor prognostic outcome in various human cancers including
SCC of the lung (Komiya et al, 1997).
Three studies have assessed the relationship between p21 and
prognosis in anal carcinoma using immunohistochemistry to
determine the level of p21 expression (Table 2) (Holm et al, 2001;
Allal et al, 2004; Nilsson et al, 2006). The study by Holm et al
(2001) included 94 patients with anal carcinoma. They reported
high p21 expression in 71% of patients with anal carcinoma
(vs 10% positivity in negative controls of normal anal squamous
epithelium). Univariate analysis demonstrated a significant
association between lack of p21 immunoreactivity and poorly
differentiated carcinomas (P¼0.004) and shorter overall survival
(P¼0.013) (Holm et al, 2001). No significant correlation was seen
between p21 expression and tumour stage or presence of nodal
metastases in this study (Holm et al, 2001). Nilsson et al (2006)
and Allal et al (2004) reported high p21 expression in 69 and 65%
of anal cancers, respectively. Both studies demonstrated a trend
towards shorter survival in p21-negative tumours, but statistical
significance was not reached (P¼0.08 and P¼0.1, respectively).
Conversely, multivariate analysis by Nilsson et al (2006) found that
patients with tumours underexpressing p21 had a significantly
higher locoregional failure rate (Po0.05).
p27 The p27 protein is a member of the CDK inhibitor family
that blocks phosphorylation of the Rb protein, thus inhibiting cell
growth and proliferation (Coate et al, 2009). Like the p21 protein,
p27 is involved in cell cycle control at the G1- to S-phase transition
(Coate et al, 2009). A Norwegian study assessed the prognostic
significance of p27 using immunohistochemistry in 94 patients
with anal carcinoma (Table 2) (Holm et al, 2001). Nuclear p27
staining was detected in 75% of cases of anal carcinoma compared
with 100% of samples of normal anal squamous epithelium (Holm
et al, 2001). No correlation was found between p27 expression and
tumour stage, lymph node involvement or overall survival (Holm
et al, 2001). The investigators did however find that reduced p27
expression was associated with moderate/highly differentiated
carcinomas (Holm et al, 2001).
p16 The p16 protein, also known as cyclin-dependent kinase
inhibitor 2A (CDKN2A), specifically targets and inhibits the
activity of CDK 4 and CDK 6, both of which are involved in cell
proliferation (Bruland et al, 2008). Studies of p16 have demon-
strated a potential prognostic role for this biomarker in
oropharyngeal SCC (Shi et al, 2009). Two recent studies consisting
of 55 and 30 patients, respectively, investigated the possible role of
p53 in predicting outcome in anal cancer (Table 2) (Bruland et al,
2008; Ajani et al, 2009). Neither study identified any association
between p16 protein expression and clinical outcome or treatment
response (Bruland et al, 2008; Ajani et al, 2009).
The RB gene The RB gene, a tumour-suppressor gene originally
found to be mutated in the rare paediatric malignancy, retino-
blastoma, encodes a nuclear protein involved in cell differentia-
tion, proliferation and apoptosis (Du and Searle, 2009). RB gene
mutations leading to loss of its tumour-suppressor function has
been identified in a variety of human malignancies (Bourgo et al,
2009; Du and Searle, 2009). One study of the RB gene in anal
carcinomas found no significant rearrangement or loss of the RB
locus in malignant (or benign) tissue (Crook et al, 1991).
Tanum and Holm (1996) evaluated 97 patients treated with
chemoradiotherapy for anal carcinoma (Table 2). Of the pre-
treatment tumour specimens, 95% stained positive for the Rb
protein. No relationship was identified between protein expression
and the clinical course of the disease.
EGFR
Four transmembrane TK proteins (HER-1 to HER-4) make up the
EGFR family of receptors that regulate cellular proliferation,
angiogenesis, apoptosis and migration via binding of specific
ligands (Neal et al, 2006; Coate et al, 2009). The intimate
association between the EGFR overexpression and cancer devel-
opment has served as a platform for the introduction of newer
therapies targeting these receptors. This is therapeutically achieved
through direct inhibition of TK or through antibody-mediated
targeting of receptors. Monoclonal antibodies directly bind to the
external domain of these TK receptors. Traztuzumab (Herceptin),
a monoclonal antibody against the HER-2 receptor, has been
widely established in breast cancer patients overexpressing HER-2
with significantly improved survival rates reported in these
Table 2 Studies of tumour suppressor-genes in anal carcinoma
Authors Year Biomarker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up
period
in months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients)
Correlation with
prognosis
Holm et al 2001 p21 94 IHC 94 chemo-
radiotherapy
0 60 71% Not reported Lack of p21 expression
associated with reduced
overall survival (P¼0.013)
Allal et al 2004 p21 98 IHC 47 radiotherapy
alone 51 chemo-
radiotherapy
0 (124) 65% 66 vs 59%
5-year DFS
No prognostic significance
identified
Nilsson et al 2006 p21 215 IHC Not reported 7 local excision,
6 APR
Not reported 69% 71 vs 62% 5 year
overall survival
Absence of p21 associated
with an increased locoregional
failure rate (Po0.05)
Holm et al 2001 p27 94 IHC 94 chemo-
radiotherapy
0 60 75% Not reported No prognostic significance
identified
Bruland et al 2008 p16 55 IHC 9 radiotherapy
alone 46 chemo-
radiotherapy
0 86.4 Not reported Not reported No prognostic significance
identified
Ajani et al 2009 p16 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼0.81
for DFS
No prognostic significance
identified
Tanum and
Holm
1996 Rb 97 IHC 97 chemo-
radiotherapy
0 (60) 95% Not reported No prognostic significance
identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; IHC¼immunohistochemistry; Rb¼retinoblastoma; RR¼relative risk.
aPatients included in final
biomarker analysis.
bIn studies where patients have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as
biomarker positive.
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spatients (Treish et al, 2000). As previously mentioned, the TK
inhibitor erlotinib has been successfully used in the treatment of
non-small cell lung cancer (Paz-Ares et al, 2006).
Tanum and Holm (1996) studied HER-2 protein expression in 97
patients with anal carcinoma who received chemoradiotherapy.
HER-2 protein expression was undetectable (Table 3) (Tanum and
Holm, 1996). Similarly, in a Canadian study of 21 patients with anal
cancer, all samples were negative for HER-2 (Le et al, 2005).
However, this study found that EGFR (HER-1) was strongly
expressed in 100% of patients (Le et al, 2005). Ajani et al (2009)
also performed immunohistochemical analysis of EGFR and reported
expression in 86% of patients with anal cancer, but no significant
correlation was observed between the degree of EGFR staining and
DFS. One study detected EGFR using immunohistochemistry in 55%
of anal SCCs. They also performed fluorescent in situ hybridisation
(FISH) to assess EGFR gene copy numbers (Alvarez et al, 2006).
There was no correlation between EGFR status and clinicopatho-
logical parameters. Furthermore, there was a lack of concordance
between the two detection techniques (Alvarez et al, 2006).
Regulators of apoptosis
Apoptosis and the genes that regulate it exert a profound effect on
the malignant phenotype in mammalian cells (Lowe and Lin, 2000)
(Table 4). Mutations in genes encoding these apoptotic regulatory
proteins can lead to tumour initiation, progression or metastasis
(Lowe and Lin, 2000).
Nuclear factor-kB (NF-kB) The nuclear transcription factor
NF-kB has been shown to prevent apoptosis through direct
inhibitory mechanisms as well as indirectly by blocking mito-
chondria-mediated apoptosis through neutralisation of reactive
oxygen species (Naugler and Karin, 2008). Moreover, poor chemo-
therapeutic responses have been attributed to NF-kB-induced
resistance to apoptosis (Naugler and Karin, 2008).
A recent study (Ajani et al, 2009) of 30 patients with anal
cancer treated with chemoradiotherapy reported that NF-kB
was an independent predictor of DFS. Multivariate analysis
revealed that patients with higher NF-kB levels, detected by
immunohistochemistry, had shorter DFS (P¼0.002) (Ajani et al,
2009).
Bcl-2, Bax and M30 The Bcl-2 family consists of at least 15
protein members including Bcl-2 and Mcl-1 that promote
cell survival by inhibiting apoptosis. They are upregulated in
certain tumour types (Lowe and Lin, 2000). Conversely, the Bax
protein is a proapoptotic molecule that functions as a down-
stream component of the p53 pathway. It has been shown to be
Table 3 Studies of the EGFR family in anal carcinoma
Authors Year Biomarker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up period
in months
Biomarker
+ve patients
b
Survival (biomarker
+ve vs  ve patients)
Correlation with
prognosis
Tanum and
Holm
1996 c-erb
B-2/HER-2
97 IHC 97 chemo-
radiotherapy
0 60 0 Not reported No prognostic significance
identified
Le et al 2005 HER-2 21 IHC 21 chemo-
radiotherapy
0 Not reported 0 Not reported No prognostic significance
identified
Le et al 2005 EGFR/HER-1 21 IHC 21 chemo-
radiotherapy
0 Not reported 100% Not reported High EGFR expression
seen in all 21 specimens
Alvarez et al 2006 EGFR/HER-1 38 IHC and
FISH
38 chemo-
radiotherapy
0 22.6 55% Not reported No prognostic significance
identified
Ajani et al 2009 EGFR/HER-1 30 IHC 30 chemo-
radiotherapy
0 Not reported 87% RR¼0.40 for DFS No prognostic significance
identified
Abbreviations: EGFR¼epidermal growth factor receptor; IHC¼immunohistochemistry; FISH¼fluorescent in situ hybridisation; RR¼relative risk.
aPatients included in final
biomarker analysis.
bIn studies where patients have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as
biomarker positive.
Table 4 Studies of apoptotic regulators in anal carcinoma
Authors Year
Bio-
marker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up period
in months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients) Correlation with prognosis
Ajani et al 2009 NF-kB 30 IHC 30 chemoradiotherapy 0 Not reported Not reported RR¼1.05
for DFS
Higher levels of NF-kB associated
with shorter DFS (P¼0.002)
Allal et al 2003 Bax 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 29% 61 vs 65%
5-year DFS
No prognostic significance
identified
Allal et al 2003 Bcl-2 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 58% 56 vs 75%
5-year DFS
Bcl-2 expression associated with
improved local tumour control
(P¼0.0015) and DFS (P¼0.001)
Le et al 2005 Bcl-2 21 IHC 21 chemoradiotherapy 0 Not reported 24% Not reported No prognostic significance
identified
Ajani et al 2009 Bcl-2 30 IHC 30 chemoradiotherapy 0 Not reported Not reported RR¼0.90
for DFS
No prognostic significance
identified
Allal et al 2003 Mcl-1 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 36% 60 vs 66%
5-year DFS
No prognostic significance
identified
Allal et al 2003 M30 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 88% 67 vs 37%
5-year DFS
Presence of M30 associated with
lower local control (P¼0.034)
and lower DFS (P¼0.03)
Abbreviations: DFS¼disease-free survival; IHC¼immunohistochemistry; NF-kB¼nuclear factor-kB; RR¼relative risk.
aPatients included in final biomarker analysis.
bIn studies
where patients have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as biomarker positive.
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smutationally inactivated in patients with SCC of the oesophagus
and this genotype correlated with poorer survival rates (Sturm
et al, 2001). The M30 protein is a monoclonal antibody that
recognises a neoepitope of cytokeratin 18 produced during
apoptosis, thus serving as a marker of spontaneous apoptosis
(Carr, 2000).
Allal et al (2003) assessed the prognostic significance of apoptotic
regulatory proteins in anal carcinoma The proportion of tumours
expressing Mcl-1 and Bcl-2 were 64 and 42%, respectively (Allal et al,
2003). Although Mcl-1 was found to have no prognostic significance,
lack of Bcl-2 expression was an independent negative factor for local
control (RR 4.66, P¼0.0015) and also for DFS (RR 4.11, P¼0.001)
(Allal et al, 2003). In the same study, Bax and M30 expression was 42
and 12%, respectively, but neither showed correlation with clinical
outcome in the 98 patients studied (Allal et al, 2003).
Two other studies have investigated Bcl-2 in patients with anal
cancer, but there was no significant association with survival
(Le et al, 2005; Ajani et al, 2009).
Cyclins
Cyclins are a family of proteins that function in conjunction with
CDKs to positively regulate specific cell cycle transition points
(Bartek and Lukas, 2001). They have been studied extensively as
regulators of cell cycle progression. The prognostic significance of
three members of the cyclin family (A, D1 and E) has been studied
in anal carcinoma (Table 5) (Allal et al, 2004; Le et al, 2005; Nilsson
et al, 2006). All three cyclins govern cell cycle progression at the
G1/S transition point, and cyclin A additionally exhibits regulatory
control at the G2/M transition point (Pagano et al, 1992). Nilsson
et al (2006) studied 215 patients with anal SCC and identified high
cyclin A expression in 51% of these patients. This was significantly
associated with better tumour-specific (81 vs 64%, P¼0.009)
and overall survival (77 vs 59%, P¼0.005) when compared with
tumours with low cyclin A expression (Nilsson et al, 2006).
Furthermore, a lower rate of isolated locoregional failure was seen
in patients with tumours expressing high levels of cyclin A
(Po0.05) (Nilsson et al, 2006). Uni- and multi-variate analyses
revealed that cyclin A was an independent predictive marker of
survival (hazard ratio 0.54, 95% CI). In the two studies of cyclin D1
and one study of cyclin E in patients with anal cancer treated with
radiotherapy±chemotherapy, pretreatment tumour levels of these
proteins were found to have no association with patient outcome
(Allal et al, 2004; Le et al, 2005).
Markers of proliferation, invasion and metastasis
Ki-67 and MiB1 Ki-67 protein is a nuclear antigen expressed in
proliferating cells. It can be detected within cells in all phases of
the cell cycle except in G0 (Gerdes et al, 1983). This nuclear antigen
expresses an epitope that is recognised by a murine monoclonal
antibody known as MiB1, and therefore the number of Ki-67/
MiB1-positive nuclei (termed the Ki-67/MiB1 index) can be used as
a marker of cellular proliferation in paraffin-embedded tumour
specimens.
Four studies have investigated the association between cellular
proliferation in anal carcinoma as determined by the Ki-67/MiB1
index and clinical outcome (Table 6) (Allal et al, 1998;
Grabenbauer et al, 1998; Indinnimeo et al, 2000b; Ajani et al,
2009). In the most recent of these studies by Ajani et al (2009),
multivariate analysis identified Ki-67 as an independent predictor
of DFS; a higher Ki-67 index correlated with longer DFS in patients
treated with chemoradiotherapy (P¼0.03). These findings are
consistent with an earlier study identifying improved colostomy-
free survival (90 vs 50%, P¼0.04) in patients with tumours of
higher proliferative potential as measured by the MiB1 index
(Grabenbauer et al, 1998). Two others studies found no association
between proliferative activity and patient survival in anal cancer
(Allal et al, 1998; Indinnimeo et al, 2000b). One study did however
report a significant correlation between Ki-67 index and depth of
tumour invasion (Po0.05) and lymph node involvement (Po0.05)
(Indinnimeo et al, 2000b).
These findings support a predictive role for Ki-67/MiB1 in the
prognosis of anal cancer patients treated with chemoradiotherapy
(Grabenbauer et al, 1998; Ajani et al, 2009). In these studies, high
Ki-67/MiB1 positivity correlated with improved survival that may
be related to heightened responses to antiproliferative chemo-
therapeutic agents. It is noteworthy that in the two studies where
no prognostic significance was found, there were a cohort of
patients who were not treated with chemotherapy but received
radiotherapy (with or without local excision) (Allal et al, 1998;
Indinnimeo et al, 2000b).
Proliferating cell nuclear antigen (PCNA) PCNA is a nuclear
protein associated with the late G1, S and early G2 phases of the cell
cycle (Shin et al, 1994). It has a vital role in DNA synthesis and
initiation of cellular proliferation. A single study has assessed the
prognostic significance of PCNA in anal carcinoma, in which
immunohistochemistry was used to analyse tumour samples
obtained from 62 patients (Table 6) (Grabenbauer et al, 1998).
There was no correlation with clinical outcome, and there have been
no novel data identifying the prognostic value of PCNA in anal SCC.
Non-metastatic protein 23 (Nm23) Studies of the nm23 protein
both in vitro and in vivo have revealed a potential role in
suppressing tumour metastasis through mechanisms that may
be dependent on its nucleoside diphosphate kinase (NDPK)
activity (MacDonald et al, 1995). Holm and Tanum (1996) studied
nm23 expression using immunohistochemical analysis in 96
patients with anal carcinoma (Table 6). Of these specimens,
Table 5 Studies of cyclins in anal carcinoma
Authors Year
Bio-
marker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up
period in
months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients) Correlation with prognosis
Nilsson et al 2006 Cyclin A 215 IHC Not reported 7 local excision,
6 APR
Not reported 51% 77 vs 59% 5-year
overall survival
High cyclin A expression associated
with improved overall (P¼0.005)
and DFS(P¼0.009)
Allal et al 2004 Cyclin D1 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 34% 57 vs 67%
5-year DFS
No prognostic significance identified
Le et al 2005 Cyclin D1 21 IHC 21 chemoradiotherapy 0 Not reported 33% Not reported No prognostic significance identified
Allal et al 2004 Cyclin E 98 IHC 47 radiotherapy
alone
51 chemoradiotherapy
0 (124) 51% 61 vs 67%
5-year DFS
No prognostic significance identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; IHC¼immunohistochemistry.
aPatients included in final biomarker analysis.
bIn studies where
patients have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as biomarker positive.
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also exhibiting positive nuclear staining (Holm and Tanum, 1996).
A correlation was identified between the presence of cytoplasmic
nm23 and shorter overall survival (P¼0.03), but no correlation
was identified between nuclear nm23 staining and survival using
univariate analysis (Holm and Tanum, 1996). These results are
contradictory with respect to its proposed function as a suppressor
of metastasis (Holm and Tanum, 1996). A smaller Italian study of
the H1subtype of the nm23 protein in 22 anal cancer patients
found no significant association between nm23 H1 expression and
prognosis (Indinnimeo et al, 2000a).
MCM7 MCM7 belongs to a family of 6 minichromosome
maintenance proteins (MCM 2–7) that have an essential role in
DNA replication and can be detected throughout the cell cycle.
They are degraded in cells that have exited the cell cycle, such as
fully differentiated cells (Tachibana et al, 2005). They have
documented potential as cancer biomarkers capable of predicting
outcome in squamous neoplasms of the oral cavity (Kodani et al,
2003). Bruland et al (2008) studied MCM7 in anal carcinoma and
found that high levels of the MCM7 gene product was significantly
associated with improved relapse-free survival (P¼0.017) and
cancer-specific survival (P¼0.011) using univariate analysis
(Table 6).
Cathepsin D Cathepsin D is a lysosomal hydrolase involved in
proteolysis and is hypersecreted in neoplastic cells (Abbott et al,
2010). Excessive production of this protein in the tumour
microenvironment promotes extracellular matrix degradation,
thereby enhancing the invasive potential of cancerous cells (Abbott
et al, 2010). Overexpression of Cathepsin D has been associated
with poorer outcome in breast carcinoma (Niu et al, 2002; Brujan
et al, 2009), although these findings have not consistently been
replicated (Cocquyt et al, 2003; Anim et al, 2005).
A single study assessed the prognostic significance of
Cathepsin D in anal cancer, and although 50% of tumours were
Cathepsin D positive, the investigators found no correlation with
overall survival (P40.10) or with the clinicopathological para-
meters of tumour stage, tumour differentiation or lymph node
involvement (Table 6) (Holm and Tanum, 1996).
Angiogenesis
Vascular endothelial growth factor (VEGF) Neovascularisation is
key to tumour invasion and metastasis, and VEGF has an
important role in this angiogenic process through interaction with
its complimentary VEGF receptors (Backer et al, 2009). Anticancer
therapies have been developed that target the VEGF receptor in
order to improve tumour response rates. Two studies have
investigated the prognostic significance of tumour VEGF levels
in anal cancer patients treated with chemoradiotherapy, but
neither study identified a correlation with patient survival (Table 7)
(Wong et al, 1999; Ajani et al, 2009).
Microvessel density (MVD) and cluster of differentiation 31
(CD31) In recent years, a widely established method of deter-
mining tumour vascularity has been through calculating MVD,
which involves identifying vascular hot spots within the tumours
and subsequently counting the number of individual micro-
vessels seen (Pathak et al, 2008). MVD can thus be considered
as a semiquantitative marker of angiogenesis. A number of
endothelial surface markers have been used to examine MVD in
malignant tumours, and among the three studies that have
assessed the prognostic significance of MVD in anal cancer, one
study used factor VIII (Wong et al, 1999) and two studies used
the CD31 molecule (Table 7) (Indinnimeo et al, 2001; Nilsson
et al, 2006). All three studies, however, failed to demonstrate a
putative role for MVD in predicting anal cancer prognosis
(Wong et al, 1999; Indinnimeo et al, 2001; Nilsson et al, 2006).
Table 6 Studies of markers of proliferation, invasion and metastasis in anal carcinoma
Authors Year
Bio-
marker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up
period in
months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients) Correlation with prognosis
Allal et al 1998 MiB1 55 IHC 31 chemo-
radiotherapy
14 radiotherapy only
0 (94) 41% 59 vs 67%
5-year DFS
No prognostic significance
identified
Grabenbauer
et al
1998 MiB1 62 IHC 62 chemo-
radiotherapy
0 (52) 34% 73 vs 50%
5-year DFS
Higher MiB1 index associated
with better colostomy-free
survival (P¼0.04)
Indinnimeo
et al
2000a,b Ki-67 31 IHC 13 chemo-
radiotherapy
7 radiotherapy
followed by
local excision
5 local excision,
6A P R
74.4 65% Not reported No prognostic significance
identified
Ajani et al 2009 Ki-67 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼0.98
for DFS
Higher levels of Ki-67 associated
with longer DFS (P¼0.005)
Grabenbauer
et al
1998 PCNA 62 IHC 62 chemo-
radiotherapy
0 (52) 32% 78 vs 45%
5-year DFS
No prognostic significance
identified
Holm and
Tanum
1996 nm23 96 IHC 96 chemo-
radiotherapy
0 60 79% Not reported Cytoplasmic nm23 expression
associated with shorter survival
P¼0.03)
Indinnimeo
et al
2000a,b nm23 22 IHC 9 chemo-
radiotherapy
5 chemotherapy
2 local excision
6A P R
63.6 27% Not reported No prognostic significance
identified
Bruland et al 2008 MCM7 55 IHC 9 radiotherapy
alone
46 chemo-
radiotherapy
0 86.4 Not reported Not reported High MCM7 correlated with
improved cancer-specific survival
(P¼0.011)
Holm and
Tanum
1996 Cathepsin D 96 IHC 96 chemo-
radiotherapy
0 60 50% Not reported No prognostic significance
identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; IHC¼immunohistochemistry; PCNA¼proliferating cell nuclear antigen; MCM7¼
mini-chromosome maintenance protein 7; nm23¼non-metastatic protein 23; RR¼relative risk.
aPatients included in final biomarker analysis.
bIn studies where patients
have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as biomarker positive.
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correlation between CD31 score and depth of tumour invasion
(Po0.05) in anal cancer, which supports the hypothesis that tumour
growth occurs through angiogenesis-dependent mechanisms.
Tumour markers
SCC antigen (SSCAg) Serum concentrations of SCCAg, a poly-
peptide subunit of a protein originally identified in malignant
human cervical tissue (Kato and Torigoe, 1977), is elevated in
several tumour sites including the anal canal (Petrelli et al, 1988;
Indinnimeo et al, 1997). Goldman et al (1993) examined the
prognostic significance of this tumour marker and reported a clear
association between SCCAg levels and survival (Table 8). Higher
pretreatment serum SCCAg levels correlated with reduced tumour-
free survival (Po0.00005) and overall survival (P¼0.02) using
multivariate analysis (Goldman et al, 1993). Another study of
SCCAg in anal cancer found no prognostic value of pretreatment
serum SCCAg, but did note that SCCAg levels were significantly
elevated in patients who had relapsed following primary treatment
(Fontana et al, 1991).
Carcinoembryonic antigen (CEA) CEA, a complex glycoprotein
that has long been established as a useful adjunct in monitoring
patients with colorectal cancer (Goldstein and Mitchell, 2005),
was investigated over a decade ago in patients with anal SCC
undergoing combined chemoradiotherapy (Table 8) (Tanum et al,
1992). Of the patients, 19% were found to have raised serum CEA
levels before treatment and 17.5% of tumours stained positive for
CEA, but no correlation with clinical outcome was observed
(Tanum et al, 1992).
Sonic hedgehog (SHH) signalling
SHH and Gli-1 Sonic hedgehog is a secreted glycoprotein
belonging to the hedgehog family of proteins that are essential to
organogenesis (Ruiz i Altaba et al, 2002). SHH triggers a complex
signal transduction pathway, the cellular response to which is
mediated by three Gli proteins (Gli-1, Gli-2 and Gli-3) (Ruiz i
Altaba et al, 2002). Gli-1 is a transcription factor that serves as an
important regulator of mammalian hedgehog signalling (Ruiz i
Altaba et al, 2002). Hedgehog signalling has been associated with
failure to respond to chemoradiotherapy and also with increased
incidence of tumour regrowth following treatment.
Ajani et al (2009) investigated the prognostic role in patients
with anal cancer treated with chemoradiotherapy. Immuno-
histochemistry was used to measure tumour SHH and Gli-1
expression. Overexpression of both markers was demonstrated
through multivariate analysis to be independent predictors of
shorter DFS (P¼0.02 and P¼0.02, respectively; Table 8).
Table 7 Studies of markers of angiogenesis in anal carcinoma
Authors Year Biomarker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment (n)
Mean (median)
follow-up period
in months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients)
Correlation with
prognosis
Wong et al 1999 VEGF 36 IHC 36 chem-
oradiotherapy
0 (54) 100% (no cutoff level
of expression reported)
Not reported No prognostic significance
identified
Ajani et al 2009 VEGF 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼0.98
for DFS
No prognostic significance
identified
Wong et al 1999 MVD 35 IHC 35 chemo-
radiotherapy
0 (54) 51% 78 vs 87%
5-year DFS
No prognostic significance
identified
Indinnimeo
et al
2001 CD31 (MVD) 24 IHC 16 chemo-
radiotherapy
2 local excision,
6 APR
(75.6) 50% Not reported No prognostic significance
identified
Nilsson et al 2006 CD31 (MVD) 209 IHC Not reported 7 local excision,
6 APR
Not reported 50% Not reported No prognostic significance
identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; IHC¼immunohistochemistry; VEGF¼vascular endothelial growth factor; MVD¼microvessel
density; CD31¼cluster of differentiation 31; RR¼relative risk.
aPatients included in final biomarker analysis.
bIn studies where patients have been differentiated by the presence
or absence of tumour biomarker overexpression, overexpression is considered as biomarker positive.
Table 8 Studies of tumour markers, hedgehog signalling and telomerase activity in anal carcinoma
Authors Year
Bio-
marker
Patients
(n)
a Method
Radio±chemo-
therapy (n)
Primary
surgical
treatment
(n)
Mean (median)
follow-up
period
in months
Biomarker
+ve patients
b
Survival
(biomarker
+ve vs  ve
patients)
Correlation with
prognosis
Fontana et al 1991 SCCAg 66 RIA Not reported Not reported 42.4 54% Not reported Correlation with relapse only in
post-treatment samples
Goldman et al 1993 SCCAg 60 RIA 59 radiotherapy 1 APR (42) 33% 43 vs 81%
5-year overall
survival
Elevated SCCAg level correlated
with reduced overall survival
(P¼0.02) and tumour-free
survival (Po0.00005).
Tanum et al 1992 CEA 106 RIA and
tissue staining
106 chemo-
radiotherapy
0 65.2 19% Not reported No prognostic significance
identified
Ajani et al 2009 SHH 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼1.03
for DFS
Higher levels of SHH associated
with shorter DFS (P¼0.02)
Ajani et al 2009 Gli-1 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼1.03
for DFS
Higher levels of Gli-1 associated
with shorter DFS (P¼0.02)
Ajani et al 2009 hTERT 30 IHC 30 chemo-
radiotherapy
0 Not reported Not reported RR¼0.98
for DFS
No prognostic significance
identified
Abbreviations: APR¼abdominoperineal resection; DFS¼disease-free survival; RAI¼radioimmunoassay; SCCAg¼squamous cell carcinoma antigen; CEA¼carcinoembryonic
antigen; SHH¼sonic hedgehog; hTERT¼human telomerase reverse transcriptase; RR¼relative risk.
aPatients included in final biomarker analysis.
bIn studies where patients
have been differentiated by the presence or absence of tumour biomarker overexpression, overexpression is considered as biomarker positive.
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proliferation and invasion is dependent on the activity of the
telomerase enzyme that is responsible for extension of chromo-
somal ends (Deville et al, 2009). The hTERT protein forms a
subunit of telomerase, and high levels of expression have been
reported in several human malignancies including lung, bladder,
oesophagus and colorectal tumours (de Kok et al, 2000). One study
of hTERT in anal cancer failed to identify a relationship between
expression of protein and patient outcome (Table 8) (Ajani et al,
2009).
DISCUSSION
Outcomes from the studies summarised in this review highlight a
spectrum of biomarkers in anal cancer that may predict patient
response to chemoradiation. Tumour-suppressor genes p53 and
p21 have been shown to be of potential prognostic value in patients
with anal cancer treated by chemoradiation, although these
findings were not found to be universal. The discordant findings
may at least in part, be explained by methodological differences
such as the choice of detection antibodies used in the immuno-
histochemical analysis. The reliability of immunostaining in
detection of p53 mutation remains uncertain, thereby affecting
detection rates and subsequent clinical correlation (Neal et al,
2006). Mutational analysis using sequencing techniques has also
been used for p53 detection in human cancers, but these
techniques have not been employed in prognostic studies of
anal carcinoma to date (Neal et al, 2006). Although clarification
of the role of p53 and p21 is required in patients treated with
chemoradiotherapy, further evaluation of their potential as
novel therapeutic targets is also essential. Although not yet
assessed in anal SCC, clinical trials of treatment of oeso-
phageal SCC with adenovirus-mediated p53 gene transfer in
combination with radiotherapy has been associated with improved
local tumour control in unresectable tumours (Oohira et al,
2004). Simultaneous vector-mediated transduction of both p53
and p21 mRNA into hepatocellular and colorectal carcinoma
cells performed in a recent study (Idogawa et al,2009) was shown
to increase rates of apoptotic cell death and also act synergis-
tically with doxorubicin, thus having important therapeutic
implications.
Since the establishment and effective use of trastuzumab
(HER-2) in the treatment of breast carcinoma, there has been a
drive to target the EGFR family of receptor proteins in other
human cancers. None of these studies of EGFR in anal cancer have
identified a direct link between EGFR status and prognosis after
chemoradiation. However, the high levels of EGFR expression seen
in anal tumours suggest that trials to investigate the activity of
both TK inhibition and antibody inhibition of EGFR signalling are
merited. It remains to be elucidated whether EGFR copy number
(Hirsch et al, 2006) and EGFR mutation status (Zhu et al, 2008)
will be markers of response to these agents in the context of anal
SCC as has been shown for lung cancers. There are likely to be
additional factors involved in determining patient responsiveness
to these agents. The K-RAS gene, encoding a protein downstream
of the EGFR receptor, has been associated with poorer responses to
EGFR inhibitors when present in a mutated form. In the setting of
colorectal cancer, it appears active only in colorectal cancers
harbouring wild-type K-RAS (Amado et al, 2008). Recent data
(Bonner et al, 2010) from a randomised trial of 424 patients with
head and neck SCC revealed that survival was prolonged when
anti-EGFR therapy (cetuximab) was combined with radiotherapy
compared with radiotherapy alone. Clearly, other potential
markers of response, such as B-RAF status, require assessment
in this context. This also appears predominantly a ‘K-RAS wild-
type’ disease according to a single small study (Zampino et al,
2009).
A single preliminary study suggested that NF-kB may be of
prognostic value in anal cancer, but there have not been any other
confirmatory studies (Ajani et al, 2009). Studies of NF-kB, most
notably haematological malignancies, demonstrate that aberrant
expression of this transcription factor is associated with tumour
growth, progression and resistance to chemotherapeutic agents
(Baud and Karin, 2009). Moreover, the use of the reversible 26S
proteosome inhibitor bortezomib, which inhibits NF-kB activity, is
an effective and approved agent in the treatment of multiple
myeloma (Baud and Karin, 2009). However, NF-kB-targeted
therapy is yet to become as widely established in other human
malignancies.
Other apoptotic regulators that were shown to correlate with anal
cancer prognosis in a single study were the Bcl-2 and M30 proteins
(Allal et al, 2003). Two other studies of Bcl-2 failed to identify a
correlation with clinical outcome (Le et al, 2005; Ajani et al, 2009).
These studies had a relatively small patient sample size and there-
fore the true prognostic impact of the Bcl-2 and other apoptotic-
regulatory molecules may need larger cohorts. In the study of
apoptosis-regulating proteins by Allal et al (2003), subgroup
analysis revealed that patients with Bcl-2-positive/p53-negative anal
tumours had significantly higher 5-year DFS compared with patients
with tumours expressing all other combinations of these two
proteins. Furthermore, results from phase III trials of oblimerson
(Genasense), an antisense nucleotide that targets Bcl-2, in chronic
lymphocytic leukaemia showed improved survival rates only when
given in conjunction with conventional chemotherapy but not when
used alone (O’Brien et al, 2007). This suggests that future
therapeutic targets may need to be used in conjunction with
cytotoxic agents or other targeted treatments.
Data from two of the four studies of Ki-67/MiB1 supported a
predictive role in the prognosis of anal cancer patients treated with
chemoradiotherapy (Grabenbauer et al, 1998; Ajani et al, 2009). In
these studies, high Ki-67/MiB1 positivity correlated with improved
survival that may be related to heightened responses to
antiproliferative chemotherapeutic agents. This is highlighted by
the fact that in the two studies where no prognostic significance
was found, there were a cohort of patients who were not treated
with chemotherapy but received radiotherapy (with or without
local excision) (Allal et al, 1998; Indinnimeo et al, 2000b). The
question therefore remains as to whether the potential prognostic
value of Ki-67/MiB1 is confined to certain treatment groups and if
individuals with highly proliferative tumours as determined by
their Ki-67/MiB1 index are likely to require more aggressive
treatment regimens.
The oncological significance of the VEGF molecule is evident
from the established use bevacizumab (Avastin), a humanised
anti-VEGF monoclonal antibody in the treatment of metastatic
breast, colorectal, renal and non-small cell lung carcinoma
(Goerner et al, 2010). The two studies of VEGF in anal cancer
reported no association with patient outcome (Wong et al, 1999;
Ajani et al, 2009). The prognostic significance of VEGF in anal
carcinoma needs further evaluation.
Investigation of molecular markers such as p16, PCNA, MVD
and the Rb protein failed to demonstrate a prognostic utility in
anal cancer. However, the degree to which these findings are
limited by methodological factors is unclear. Other proteins such
as M30, cyclin A, SCCAg, SHH and Gli-1 were demonstrated to be
of predictive value in individual studies but further trials are
required to reproduce these findings.
Other cancers related to HPV infection continue to increase in
incidence. HPV-associated head and neck SCC is associated with
HPV 16 similar to anogenital SCCs. In situ hybridisation studies
have demonstrated that HPV status correlates (Kuo et al, 2008)
with treatment response, progression-free survival and overall
survival in oropharyngeal SCC (Fakhry et al, 2008; Ang et al, 2010).
In this setting, much debate exists regarding the optimal detection
technique and whether P-16 should be used as a surrogate marker.
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to anal cancer with the potential for vaccine therapy in established
HPV-associated disease. The National Cancer Institute Phase II trial
has completed accrual in studying the effectiveness of human
papillomavirus vaccine (HPV-16 E-6 and E-7 peptides) therapy in
treating patients who have advanced or recurrent cancer of the cervix,
v a g i n a ,p e n i s ,a n u s ,o e s o p h a g u s , or head and neck (National Cancer
Institute, 2009). We await the results of these and other studies.
There is a growing appreciation of the fact that all clinical trials
of emerging targeted treatments must incorporate biomarkers
studies in order to minimise the possibility of failing to appreciate
significant activity of the drug in a biological subset of a given cancer
type and to maximise the chance of response in a given patient. This
is all the more essential in the case of anal carcinoma, which is an
uncommon cancer type that will limit the patient numbers available
for clinical trials. Certainly, there are targeted treatments that have
been shown to have activity in other EGFR-expressing cancers that
need assessment in this tumour type, and biomarkers that have been
shown to be helpful in other cancer sites should be prioritised for
assessment. Any biomarker studies and validation thereof should
aim to comply with Biomarker Task Force recommendations in
order to ensure that results can be assessed in terms of realistic
clinical utility (Dancey et al,2 0 1 0 ) .
CONCLUSION
Biomarkers in anal cancer may possess the ability to tailor
treatment to individuals. Certain markers such as the EGFR
protein are potential treatment targets in this disease. It remains
to be seen if biomarkers of response to anti-EGFR therapies
shown to be of use in other carcinoma types are applicable to anal
carcinoma. Larger prospective studies of single or panels of
multiple biomarkers are necessary with standardised methodology.
Novel study designs are required and future prospects include the
use of DNA microarray-based gene expression profiling that has
already been shown to provide valuable prognostic information in
patients with breast cancer (Munkacsy et al, 2010). Pharmaco-
genomics has the potential to make a major contribution to
biomarker identification and future directions of therapy in anal
cancer. Within its realm, single-nucleotide polymorphism (SNP)
analysis serves as a promising avenue for future research studies.
Although the quest for prognostic markers in anal cancer is
currently in its early stages, expanding research into this field
is driven by the prospect of unravelling molecular characteristics
of these tumours that may ultimately prolong patient survival
and reduce the health and economic burden of this disease
epidemic.
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